YOLFTbeta
ARS Pharmaceuticals, Inc

ARS Pharmaceuticals, Inc

SPRY · NASDAQ · Healthcare / Biotechnology

3.89USD+0.08 (+2.10%)

Price History

Full chart

Market Stats

Previous Close3.81
Open3.86
Day Range3.79 – 4.00
52-Week Range4.00 – 13.15
Volume1.30M
Market Cap410.72M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.18
Dividend Yield0.00%
Beta1.00
50-Day Avg5.48
200-Day Avg8.26

About

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Donn Casale
  • Employees195
  • Headquarters11682 El Camino Real, San Diego, CA, United States, 92130, USA
  • Websitehttps://ars-pharma.com

Leadership

  • Mr. Justin ChakmaChief Business Officer · b. 1990
  • Mr. Donn CasaleCEO, President & Director · b. 1973
  • Dr. Robert Bell Ph.D.Co-Founder & Chief Science Officer
  • Ms. Kathleen D. Scott CPAChief Financial Officer
  • Mr. Brian T. Dorsey M.S.Chief Operating Officer · b. 1969
  • Mr. Alexander A. Fitzpatrick Esq.Chief Legal Officer & Secretary · b. 1967
  • Mr. Daniel RelovskySenior Vice President of Marketing
  • Ms. Lynda HarrisVice President of Human Resources
  • Mr. Eric KarasChief Commercial Officer · b. 1973

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--17.84M5.51M1.32M30.00K89.15M84.28M
Growth (%)----69.13%-76.10%-97.72%+297063.33%-5.46%
Cost of Revenue1.42M1.55M14.07M213.00K17.12M73.00K20.56M20.42M
Gross Profit-1.42M-1.55M3.77M5.29M-15.80M30.00K68.59M63.85M
Gross Margin--21.11%96.13%-1200.91%100.00%76.94%75.77%
Operating Expense16.90M22.52M4.23M24.75M19.71M67.55M71.67M243.30M
Operating Income-18.32M-24.07M-469.00K-19.45M-35.52M-67.52M-3.08M-179.45M
Operating Margin---2.63%-353.32%-2698.78%-225066.67%-3.46%-212.92%
EBITDA-16.90M-22.52M-463.00K-19.92M-34.36M-54.29M8.37M-167.41M
EBITDA Margin---2.60%-361.86%-2611.17%-180973.33%9.38%-198.64%
Net Income-17.58M-23.97M-1.06M-20.24M-34.68M-54.37M8.00M-171.30M
Net Income Margin---5.97%-367.65%-2635.41%-181216.67%8.97%-203.25%
R&D14.80M21.50M14.07M20.27M18.38M20.27M19.58M13.18M
R&D as % of Total Revenue--78.89%368.20%1396.35%67553.33%21.96%15.64%
Interest Expense--29.00K106.00K834.00K-02.60M
Interest Expense % of Total Revenue--0.16%1.93%63.37%-0.00%3.08%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.55M15.65M26.41M61.45M281.44M233.19M351.15M327.65M
Total Liabilities9.35M21.25M40.46M92.72M8.55M2.43M94.36M213.39M
Total Equity18.20M-5.60M-14.05M-31.27M272.89M230.76M256.80M114.26M
Cash20.16M9.98M24.52M60.06M210.52M70.97M50.82M41.32M
Total Debt7.73M15.62M10.02M9.03M481.00K274.00K42.00K96.37M
Net Debt-12.43M5.64M-14.50M-51.03M-210.04M-70.70M-50.77M55.06M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.88M-18.90M9.07M-17.56M-40.08M-59.27M13.55M-170.87M
Investing Cash Flow-449.00K-96.00K-917.00K-55.00K-199.00K-87.18M-106.10M56.77M
Financing Cash Flow19.40M8.61M5.10M53.16M190.73M6.90M72.40M104.60M
Capital Expenditure449.00K96.00K917.00K55.00K199.00K175.00K563.00K339.00K
Free Cash Flow-17.32M-18.99M8.15M-17.62M-40.28M-59.44M12.98M-171.21M
FCF to OCF102.66%100.51%89.89%100.31%100.50%100.30%95.84%100.20%

Earnings

Report DateNov 10, 2020Mar 29, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 31, 2022May 12, 2022Aug 11, 2022Nov 2, 2022Mar 23, 2023May 15, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 9, 2024Aug 6, 2024Nov 13, 2024Mar 19, 2025May 14, 2025Aug 13, 2025Nov 10, 2025Mar 19, 2026May 15, 2026Aug 13, 2026Nov 9, 2026
EPS Estimate-1.10-0.49-0.35-0.53-0.67-0.70-0.54-0.48-0.35-0.13-0.15-0.16-0.18-0.14-0.11-0.11-0.14-0.12-0.36-0.51-0.49-0.42-0.53-0.55-0.33
EPS Actual-0.70-1.37-0.54-0.70-0.65-0.67-0.70-0.55-0.500.77-0.16-0.18-0.16-0.07-0.11-0.13-0.200.51-0.35-0.46-0.52-0.42-0.61-0.63-
Surprise36.36%-179.59%-54.29%-32.08%2.99%4.29%-29.63%-14.58%-42.86%692.31%-6.67%-12.50%11.11%50.00%0.00%-18.18%-42.86%534.04%2.78%9.80%-6.12%1.08%-15.09%-14.55%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap410.72M
Enterprise Value369.02M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.51
Price / Book33.26
EPS-2.18
Book Value0.126
Revenue (TTM)116.93M
Gross Profit (TTM)68.22M
EBITDA-214.65M
Profit Margin-184.24%
Operating Margin-182.62%
Return on Equity-210.35%
Return on Assets-48.02%
Shares Outstanding99.45M
Shares Float48.03M
Beta1.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 22.50
  • Strong Buy
    5
  • Buy
    1

Ownership Breakdown

Institutions
92.08%
Insiders
16.18%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    10.86M10.92%
  • Orbimed Advisors LLC
    8.29M8.33%
  • Rubric Capital Management LP
    8.00M8.04%
  • Deerfield Management Co
    7.50M7.55%
  • BlackRock Inc
    5.01M5.04%
  • Tyro Capital Management LLC
    4.46M4.48%
  • Aberdeen Group PLC
    4.17M4.19%
  • SR ONE CAPITAL MANAGEMENT, LP
    4.01M4.04%
  • State Street Corp
    3.64M3.67%
  • Franklin Templeton Inc
    3.28M3.30%
  • Capital World Investors
    2.75M2.77%
  • Vanguard Capital Management, LLC
    2.54M2.56%
  • Millennium Management LLC
    2.40M2.41%
  • UBS Group AG
    2.26M2.27%
  • Janney Montgomery Scott LLC
    2.02M2.03%
  • Geode Capital Management, LLC
    1.53M1.54%

Top Fund Holders

  • American Funds SMALLCAP World A
    2.68M2.70%
  • State Street® SPDR® S&P® Biotech ETF
    2.41M2.43%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.75M1.76%
  • iShares Russell 2000 ETF
    1.58M1.59%